Manila Times Business
Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update
Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance with Nasdaq stockholders’ equity requirement Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos” or the "Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatme
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
The Weaver AI Capital Advisors Ltd Details Its Cross-Border Retirement Planning Approach and Corporate Update
1h ago
From Physics to Factory: NAED’s PV-1 Delivers the Tandem Era at 96,000 WPH
1h ago
PEGATRON Advances Agentic AI and HPC Infrastructure with High-Density Computing Solutions at SC26
1h ago
Northern Discovery Metals Announces Closing of First Tranche of Private Placement
2h ago